Departed
James L. Cox, M.D.
Director
PAVM ·
PAVmed Inc.
James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.
Ready 8-Ks
36
Latest filing
May 15, 2026, 8:05 AM ET
Top materiality
0.90
Event mix
other_material ×19 · earnings ×9 · regulatory ×4
Sentiment
5 pos · 7 neg · 24 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for PAVM
Highest-materiality recent filing
PAVmed exchanges $22.3M convertible notes for Series C Preferred Stock and enters separate $2.65M purchase
- Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.
- Series C Preferred Stock carries 7.875% annual dividend, convertible at $1.068 per share, and redeemable at 132.5% of stated value.
-
PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests
GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
-
PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M
PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.
-
PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities
Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.
-
PAVmed announces 1-for-30 reverse stock split effective Jan 2, 2026 to regain Nasdaq compliance
1-for-30 reverse split effective Jan 2, 2026; authorized shares reduced from 250M to 25M.
-
PAVmed shareholders approve reverse stock split (1:10–1:30) and authorized share reduction to 25M
Stockholders approved reverse split (ratio 1:10–1:30, board to decide) and authorized share reduction from 250M to 25M.
-
PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support
GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.
-
PAVmed subsidiary Lucid Diagnostics closes $28.75M stock offering at $1.00/share
Lucid Diagnostics sold 28.75M shares at $1.00 each via underwritten offering.
-
PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests
GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).
-
PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price
Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.
-
PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M
GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).
-
PAVmed enters $2.88M at-the-market equity offering agreement with Maxim Group
ATM offering up to $2,880,000 of common stock under shelf registration effective April 15, 2025.
-
PAVmed subsidiary Lucid Diagnostics closes 14.4M share offering raising ~$16.1M net
Lucid Diagnostics closed sale of 14,375,000 shares at $1.20 each, including full exercise of underwriters' option.
-
PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured
GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.
-
PAVmed raises $2.37M via PIPE of common stock and pre-funded warrants with Veris subsidiary shares
Sale of 2,574,350 shares and 756,734 pre-funded warrants at $0.7115/unit; Veris issues 677,143 shares to investors.
-
PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares
Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.
-
PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance
Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.
-
PAVmed stockholders approve 4x increase in authorized shares to 250M and Series C Preferred issuance
Stockholders approved amending the certificate of incorporation to increase authorized common shares from 50M to 250M, effective Jan 15, 2025.
-
PAVmed sub Lucid closes $21.95M convertible note placement; net $18.3M
Lucid Diagnostics (PAVmed sub) closed $21.95M in Senior Secured Convertible Notes to accredited investors.
-
Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.
-
Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.
-
Deconsolidated Lucid from financials; expects ~$70M non-cash gain in Q3 2024.
-
PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)
Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).
-
PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M
GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).
-
PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering
Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.
-
Veris and OSUCCC-James signed MOU to pilot the Veris Cancer Care Platform for cancer patients.
-
PAVmed extends senior secured note maturities to 2025; pays $2M for covenant waiver
April 2022 Note maturity extended to April 4, 2025; September 2022 Note to September 8, 2025.
-
PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange
Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.
Executive changes
Appointed
Sundeep Agrawal, M.D.
Class B Director
PAVM ·
PAVmed Inc.
the Company’s board of directors appointed Sundeep Agrawal, M.D. as a Class B director.
Departed
Joan B. Harvey
Director
PAVM ·
PAVmed Inc.
James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material